Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2008-03-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Turmeric
diabetic nephropathy patient
more than 300 mg/proteinuria
Turmeric extract
turmeric 500 mg TID for 45 days
ACE inhibitor + ATI blocker
diabetic nephropathy
more than 300 mg/day proteinuria
Turmeric extract
turmeric 500 mg TID for 45 days
Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
maximum dosage as patient tolerated for 45 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Turmeric extract
turmeric 500 mg TID for 45 days
Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
maximum dosage as patient tolerated for 45 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* more than 300 mg proteinuria/day
* age more than 18 years old
Exclusion Criteria
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Shaheed Faghihi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shiraz University of Medical Science
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
maryam pakfetrat, assistant professor
Role: PRINCIPAL_INVESTIGATOR
Shiraz nephro-urology research center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinic
Shiraz, Fars, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3997
Identifier Type: -
Identifier Source: org_study_id